Product Description

🔹 Product Overview
Guficol 3 MIU Injection is a prescription antibiotic containing Colistimethate Sodium 3 Million IU (3 MIU). It is used under medical supervision for the treatment of serious bacterial infections, particularly when other appropriate antibiotics may not be suitable.
Active ingredient: Colistimethate Sodium 3 MIU
Drug class: Polymyxin antibiotic
Dosage form: Injection
Therapeutic category: Anti-infective
Manufactured by Gufic Bioscience Ltd.
Generally administered by a healthcare professional in a hospital or clinical setting

🔹 Key Uses
Guficol 3 MIU Injection may be used for the treatment of severe bacterial infections, particularly infections caused by susceptible bacteria. It may be considered in critically ill patients when treatment with other antibiotics is unsuitable or when resistant bacterial infections are suspected or confirmed.
Depending on the infection and clinical assessment, colistimethate may be used in the management of serious infections involving areas such as:
Lungs and respiratory tract
Urinary tract
Bloodstream
Other sites of severe bacterial infection
The exact indication should be determined by the treating physician based on microbiological results and the patient's clinical condition.

🔹 Composition
Active ingredient: Colistimethate Sodium 3 Million IU (3 MIU)
Belongs to the polymyxin group of antibiotics
Supplied as an injectable formulation
Designed for use against susceptible Gram-negative bacteria
The product is listed by Gufic under its Criti Care anti-infective range.

🔹 How It Works
Colistimethate is a prodrug that is converted to colistin, the active antibacterial compound.
Colistin interacts with the bacterial cell membrane, disrupting its integrity and causing leakage of cellular contents. This damages the bacterial cell and can ultimately lead to bacterial death.
Because colistin is generally reserved for serious infections involving resistant organisms, its use requires careful medical assessment and monitoring.

🔹 Key Benefits
Used for serious bacterial infections caused by susceptible organisms
Provides an option for infections involving certain resistant Gram-negative bacteria
Can be administered under controlled hospital or clinical conditions
Particularly important when alternative antibiotic treatments may not be appropriate
Treatment benefits depend on the type of bacteria, infection site, antibiotic susceptibility, dose, and the patient's overall medical condition.

🔹 Dosage and Administration
Guficol 3 MIU Injection should be administered only by a qualified healthcare professional.
Dose and treatment duration are determined by the treating physician
Dosing may need adjustment according to kidney function
It may be administered intravenously according to the prescribed regimen
Do not self-administer this injection
The complete treatment course should be followed as prescribed
Blood tests and kidney-function monitoring may be required during treatment
The dose should not be calculated or changed without medical supervision because colistimethate dosing requires careful consideration of the patient's clinical condition and renal function.

🔹 Possible Side Effects
Possible adverse effects associated with colistimethate may include:
Dizziness
Tingling or numbness (paresthesia)
Weakness
Gastrointestinal disturbances
Injection-related reactions
Changes in kidney function
Electrolyte disturbances
Neurological effects

Serious kidney or neurological reactions can occur and require prompt medical evaluation.
Inform the treating healthcare professional immediately if unusual weakness, severe dizziness, difficulty breathing, reduced urine output, or other concerning symptoms develop.

🔹 Precautions
Before treatment with Guficol 3 MIU Injection, inform your doctor if you have:
Kidney disease or reduced kidney function
Neurological disorders
Breathing problems
Previous allergy to colistimethate, colistin, or related antibiotics
A history of significant electrolyte abnormalities